IL112193A - 6-(2-arylpyrazolo¬1,5-A¾pyridine-3-yl)-2-substituted pyridazin-3(2H)-one derivatives processes for the preparation thereof and pharmaceutical compositions containing them - Google Patents

6-(2-arylpyrazolo¬1,5-A¾pyridine-3-yl)-2-substituted pyridazin-3(2H)-one derivatives processes for the preparation thereof and pharmaceutical compositions containing them

Info

Publication number
IL112193A
IL112193A IL11219394A IL11219394A IL112193A IL 112193 A IL112193 A IL 112193A IL 11219394 A IL11219394 A IL 11219394A IL 11219394 A IL11219394 A IL 11219394A IL 112193 A IL112193 A IL 112193A
Authority
IL
Israel
Prior art keywords
arylpyrazolo
preparation
pharmaceutical compositions
compositions containing
derivatives processes
Prior art date
Application number
IL11219394A
Other languages
English (en)
Other versions
IL112193A0 (en
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9326524A external-priority patent/GB9326524D0/en
Priority claimed from GB9404323A external-priority patent/GB9404323D0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of IL112193A0 publication Critical patent/IL112193A0/xx
Publication of IL112193A publication Critical patent/IL112193A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11219394A 1993-12-29 1994-12-29 6-(2-arylpyrazolo¬1,5-A¾pyridine-3-yl)-2-substituted pyridazin-3(2H)-one derivatives processes for the preparation thereof and pharmaceutical compositions containing them IL112193A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9326524A GB9326524D0 (en) 1993-12-29 1993-12-29 New compound
GB9404323A GB9404323D0 (en) 1994-03-04 1994-03-04 New compound

Publications (2)

Publication Number Publication Date
IL112193A0 IL112193A0 (en) 1995-03-15
IL112193A true IL112193A (en) 2000-10-31

Family

ID=26304101

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11219394A IL112193A (en) 1993-12-29 1994-12-29 6-(2-arylpyrazolo¬1,5-A¾pyridine-3-yl)-2-substituted pyridazin-3(2H)-one derivatives processes for the preparation thereof and pharmaceutical compositions containing them

Country Status (11)

Country Link
US (2) US5773530A (xx)
EP (1) EP0737193A1 (xx)
JP (1) JP3572617B2 (xx)
KR (1) KR100386542B1 (xx)
CN (1) CN1046724C (xx)
AU (1) AU694157B2 (xx)
CA (1) CA2180253A1 (xx)
HU (1) HUT76280A (xx)
IL (1) IL112193A (xx)
TW (1) TW369535B (xx)
WO (1) WO1995018128A1 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2180253A1 (en) * 1993-12-29 1995-07-06 Atsushi Akahane Pyrazolopyridine adenosine antagonists
EP0900796B1 (en) * 1996-04-25 2004-12-15 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for ischemic intestinal lesion and ileus
AU733034B2 (en) * 1996-07-18 2001-05-03 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
WO1998041237A1 (fr) 1997-03-18 1998-09-24 Fujisawa Pharmaceutical Co., Ltd. Medicaments pour la prevention et la therapie de l'hyperphosphatemie
US6521656B1 (en) * 1998-06-01 2003-02-18 Fujisawa Pharmaceutical Co., Ltd. Remedies for male sterility
WO1999067239A1 (fr) * 1998-06-22 1999-12-29 Fujisawa Pharmaceutical Co., Ltd. Composes pyrazolopyridiniques et leur utilisation comme medicaments
AUPP672198A0 (en) * 1998-10-23 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
KR100694684B1 (ko) 1999-07-02 2007-03-13 에자이 알앤드디 매니지먼트 가부시키가이샤 축합 이미다졸 화합물 및 당뇨병 치료약
AUPQ441499A0 (en) * 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US6919352B2 (en) * 2000-12-15 2005-07-19 Smithkline Beecham Corporation Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
AU2002248531A1 (en) * 2001-03-08 2002-09-24 Smithkline Beecham Corporation Pyrazolopyriadine derivatives
ATE332301T1 (de) * 2001-04-10 2006-07-15 Smithkline Beecham Corp Antivirale pyrazolopyridin verbindungen
ES2242028T3 (es) 2001-04-27 2005-11-01 Smithkline Beecham Corporation Derivados de pirazolo(1,5-a)piridina.
AUPR548601A0 (en) * 2001-06-06 2001-06-28 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyrazinecompound and pharmaceutical use thereof
WO2004033454A1 (en) * 2002-10-03 2004-04-22 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
US7891808B2 (en) * 2008-12-08 2011-02-22 Alexsey Mazurenko Magnification viewer with loupe mounting assembly
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9790203B2 (en) * 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
MA45362A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MA45154A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères
MD3464306T2 (ro) 2016-05-24 2024-08-31 Sarepta Therapeutics Inc Procedee de preparare a oligomerilor morfolino fosforodiamidați
AU2017270598B2 (en) * 2016-05-24 2022-12-01 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
EP3941475A4 (en) * 2019-03-20 2023-01-25 Goldfinch Bio, Inc. PYRIDAZINONES AND THEIR METHODS OF USE

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179103A (en) * 1987-06-15 1993-01-12 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US5338743A (en) * 1988-06-06 1994-08-16 Fujisawa Pharmaceutical Co., Ltd. New use of the adenosine antagonist
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9107513D0 (en) * 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
CA2180253A1 (en) * 1993-12-29 1995-07-06 Atsushi Akahane Pyrazolopyridine adenosine antagonists
EP0900796B1 (en) * 1996-04-25 2004-12-15 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for ischemic intestinal lesion and ileus

Also Published As

Publication number Publication date
CA2180253A1 (en) 1995-07-06
US6355640B1 (en) 2002-03-12
KR100386542B1 (ko) 2003-10-11
HUT76280A (en) 1997-07-28
AU1281795A (en) 1995-07-17
JP3572617B2 (ja) 2004-10-06
EP0737193A1 (en) 1996-10-16
CN1046724C (zh) 1999-11-24
WO1995018128A1 (en) 1995-07-06
IL112193A0 (en) 1995-03-15
CN1139928A (zh) 1997-01-08
JPH09507485A (ja) 1997-07-29
US5773530A (en) 1998-06-30
AU694157B2 (en) 1998-07-16
KR970700189A (ko) 1997-01-08
TW369535B (en) 1999-09-11
HU9601789D0 (en) 1996-09-30

Similar Documents

Publication Publication Date Title
IL112193A (en) 6-(2-arylpyrazolo¬1,5-A¾pyridine-3-yl)-2-substituted pyridazin-3(2H)-one derivatives processes for the preparation thereof and pharmaceutical compositions containing them
IL134688A (en) CYCLOOXYGENASE 2 INHIBITING 2, 3-DIARYL-PYRAZOLO [1, 5-b] PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
HUP0002104A3 (en) Pyrazolo[3,4-d]pyrimidinedione derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0003999A3 (en) Fused 1,2,4-thiadiazine derivatives, their preparation, their use and pharmaceutical compositions containing them
HUP9701596A3 (en) 2,4-diamino-1,3,5-triazine derivatives, process for their preparation, their use for the preparation of pharmaceutical compositions and the pharmaceutical compositions containing them
HUP9800138A3 (en) 8-substituted-1,3,8-triaza-spiro [4,5]-decan-4-on derivatives, process for producing them, pharmaceutical compositions containing the same and their use
IL107231A0 (en) Pyrazole derivatives, processes for the preparation thereof and herbicidal compositions containing the same
ZA931637B (en) Pyrrolobenzodiazepine derivatives, their preparation and compositions containing them
IL110286A0 (en) Pyrido(2,3-d) pyridazin-5-one and pyrido(2,3-d)pyridazin-5-thione derivatives, processes for their preparation and herbicidal compositions containing them
HUP0004225A3 (en) Pyridine derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same
NZ238288A (en) Pyrazolo- and triazolo-(1,3,5)triazine derivatives; processes and pharmaceutical compositions
IL111533A0 (en) Quinoxalinedione derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
IL98873A0 (en) Benzodiazepine derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
NZ232168A (en) Perhydropyrido(1,2-a)pyrazine derivatives; intermediates and pharmaceutical compositions
ZA985121B (en) 3-Substituted 3,4-dihyrothieno(2,3-d)pyrimidine derivatives their preparation and use.
NZ322197A (en) Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
IL104706A0 (en) 3-(1h-tetrazol-5-yl)-4h-pyrido(1,2-a)pyrimidine-4-ones and process for the preparation thereof
IL87542A0 (en) Arylenediamino substituted triazine derivatives,processes for the preparation thereof and compositions containing the same
IL108502A (en) 4-benzoylisoxazole derivatives, processes for their preparation and herbicidal compositions containing them
HUP9801256A3 (en) 5'-deoxy-cytidine derivatives, preparation and use thereof and pharmaceutical compositions
EP0584487A3 (en) 4,5-dihydro-4-oxopyrrolo (1,2-a) quinoxalines and aza-analoges and process for their preparation
IL118485A (en) 5,6-dihydro-9H-pyrazolo¬3,4-c¾-1,2,4-triazolo¬4,3-a¾ pyridines and pharmaceutical compositions containing them
ZA929903B (en) 3(2H)-pyridazinone derivatives and process for the preparation thereof.
IL97931A0 (en) Pyridazine derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0002650A3 (en) 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b]-indole-1-acetamide derivatives, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees